Could a Mind-Body exercise program ease scleroderma symptoms?
NCT ID NCT07292961
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a structured exercise program called BETY, which focuses on the whole person (body, mind, and social factors), in 48 children and adults with scleroderma. Participants will either do the BETY program for 3 months or follow a home exercise routine. The goal is to see if BETY improves skin health, movement, and overall well-being.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cognitive Exercise Therapy Approach (BETY) - a structured exercise program based on the biopsychosocial model
- What this could lead to
- If it works, this could offer a safe, non-drug way to improve physical function, skin health, and quality of life for people with scleroderma.
- What could go wrong
- This is a small early-stage trial with only 48 participants, so results may not apply to everyone. The exercise program requires commitment, and benefits may be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JUVENILE SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hacettepe University
RECRUITINGAnkara, Altındağ, 06100, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can skin biopsies unlock new treatments for scleroderma?
- Could a skin patch ease stomach pain in scleroderma?
- Could a painless microneedle pad ease Raynaud's in scleroderma?
- Can a new pill ease the hardening skin of systemic sclerosis?
- A drug after transplant may stop scleroderma from coming back
- Can a single drug calm three different autoimmune diseases? a new trial puts ATG-201 to the test.